Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies
Talaromycosis (TM) is an invasive fungal infection caused by <i>Talaromyces marneffei</i> (<i>T. marneffei</i>). It has high morbidity and mortality rates, particularly among immunocompromised people. Globally, approximately 17,300 cases and 4900 deaths are reported annually....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Journal of Fungi |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2309-608X/11/6/434 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849705127358758912 |
|---|---|
| author | Yihui Wang Xiaoyue Wang Liyan Xi Sha Lu |
| author_facet | Yihui Wang Xiaoyue Wang Liyan Xi Sha Lu |
| author_sort | Yihui Wang |
| collection | DOAJ |
| description | Talaromycosis (TM) is an invasive fungal infection caused by <i>Talaromyces marneffei</i> (<i>T. marneffei</i>). It has high morbidity and mortality rates, particularly among immunocompromised people. Globally, approximately 17,300 cases and 4900 deaths are reported annually. TM often has vague clinical signs with limited current tests, leading to misdiagnosis, incorrect treatments, or the long-term use of expensive antifungal drugs, which raises healthcare costs and patient risks. Although accurate diagnosis is key for starting the right antifungal therapy and improving outcomes, there are not enough reliable and fast tests. Recent progress with monoclonal antibodies (mAbs) that have high specificity for antigens may boost diagnostic accuracy and cut misdiagnosis rates. This review explores current ways to diagnose TM, including culture, histopathology, and molecular methods such as polymerase chain reaction (PCR) and antigen detection. We also discuss the merits and weaknesses of each method and highlight how mAbs may help diagnose TM. We searched PubMed, Web of Science, and Google Scholar for English-language papers (1990—1 January 2025) using “Talaromycosis” OR “<i>Talaromyces marneffei</i>” plus diagnostic terms (‘diagnosis’, ‘molecular diagnostics’, ‘monoclonal antibody’, ‘lateral flow’, ‘antigen detection’, and ‘fungal diagnosis’). After deduplication and relevance screening, studies with original data or substantive discussion on <i>T. marneffei</i> diagnostics or mAb development were retained to inform this narrative review. |
| format | Article |
| id | doaj-art-b8a4f7d5474845b09e729d18fb0ea4c6 |
| institution | DOAJ |
| issn | 2309-608X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Fungi |
| spelling | doaj-art-b8a4f7d5474845b09e729d18fb0ea4c62025-08-20T03:16:33ZengMDPI AGJournal of Fungi2309-608X2025-06-0111643410.3390/jof11060434Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging TechnologiesYihui Wang0Xiaoyue Wang1Liyan Xi2Sha Lu3Department of Dermatology and Venereology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, ChinaDepartment of Dermatology and Venereology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, ChinaDepartment of Dermatology and Venereology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, ChinaDepartment of Dermatology and Venereology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, ChinaTalaromycosis (TM) is an invasive fungal infection caused by <i>Talaromyces marneffei</i> (<i>T. marneffei</i>). It has high morbidity and mortality rates, particularly among immunocompromised people. Globally, approximately 17,300 cases and 4900 deaths are reported annually. TM often has vague clinical signs with limited current tests, leading to misdiagnosis, incorrect treatments, or the long-term use of expensive antifungal drugs, which raises healthcare costs and patient risks. Although accurate diagnosis is key for starting the right antifungal therapy and improving outcomes, there are not enough reliable and fast tests. Recent progress with monoclonal antibodies (mAbs) that have high specificity for antigens may boost diagnostic accuracy and cut misdiagnosis rates. This review explores current ways to diagnose TM, including culture, histopathology, and molecular methods such as polymerase chain reaction (PCR) and antigen detection. We also discuss the merits and weaknesses of each method and highlight how mAbs may help diagnose TM. We searched PubMed, Web of Science, and Google Scholar for English-language papers (1990—1 January 2025) using “Talaromycosis” OR “<i>Talaromyces marneffei</i>” plus diagnostic terms (‘diagnosis’, ‘molecular diagnostics’, ‘monoclonal antibody’, ‘lateral flow’, ‘antigen detection’, and ‘fungal diagnosis’). After deduplication and relevance screening, studies with original data or substantive discussion on <i>T. marneffei</i> diagnostics or mAb development were retained to inform this narrative review.https://www.mdpi.com/2309-608X/11/6/434talaromycosis<i>Talaromyces marneffei</i>diagnosismonoclonal antibodymolecular diagnostics |
| spellingShingle | Yihui Wang Xiaoyue Wang Liyan Xi Sha Lu Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies Journal of Fungi talaromycosis <i>Talaromyces marneffei</i> diagnosis monoclonal antibody molecular diagnostics |
| title | Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies |
| title_full | Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies |
| title_fullStr | Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies |
| title_full_unstemmed | Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies |
| title_short | Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies |
| title_sort | advancements in diagnosing talaromycosis exploring novel strategies and emerging technologies |
| topic | talaromycosis <i>Talaromyces marneffei</i> diagnosis monoclonal antibody molecular diagnostics |
| url | https://www.mdpi.com/2309-608X/11/6/434 |
| work_keys_str_mv | AT yihuiwang advancementsindiagnosingtalaromycosisexploringnovelstrategiesandemergingtechnologies AT xiaoyuewang advancementsindiagnosingtalaromycosisexploringnovelstrategiesandemergingtechnologies AT liyanxi advancementsindiagnosingtalaromycosisexploringnovelstrategiesandemergingtechnologies AT shalu advancementsindiagnosingtalaromycosisexploringnovelstrategiesandemergingtechnologies |